Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TLSA 
Tiziana Life Sciences Ltd (TLSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: TLSA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -7.69% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 186.96M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 0.11 | 52 Weeks Range 0.63 - 1.91 | Updated Date 06/29/2025 |
52 Weeks Range 0.63 - 1.91 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.11 |
Earnings Date
Report Date 2025-06-23 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -84.13% | Return on Equity (TTM) -250.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 183338371 | Price to Sales(TTM) - |
Enterprise Value 183338371 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.98 | Shares Outstanding 116848000 | Shares Floating 63394363 |
Shares Outstanding 116848000 | Shares Floating 63394363 | ||
Percent Insiders 43.06 | Percent Institutions 2.73 |
Upturn AI SWOT
Tiziana Life Sciences Ltd
Company Overview
History and Background
Tiziana Life Sciences Ltd is a biotechnology company founded in 2014. It focuses on developing innovative therapeutics for oncology, inflammation, and infectious diseases. The company has evolved from a focus on monoclonal antibodies to include small molecule research and development.
Core Business Areas
- Immunotherapy: Development of monoclonal antibodies for cancer and inflammatory diseases.
- Targeted Therapeutics: Development of small molecule drugs targeting specific disease pathways.
- COVID-19 Therapeutics: Development of therapies to treat COVID-19 and its related complications.
Leadership and Structure
The leadership team consists of a CEO, CFO, CSO, and a board of directors. The company structure is organized around research, development, and commercialization divisions.
Top Products and Market Share
Key Offerings
- Foralumab: An anti-CD3 monoclonal antibody in development for Crohn's disease, non-alcoholic steatohepatitis (NASH), and other inflammatory and autoimmune diseases. No current market share data. Competitors include AbbVie (Humira) and Janssen (Stelara).
- Milciclib: A small molecule inhibitor of cyclin-dependent kinases (CDKs) in development for hepatocellular carcinoma (HCC). No current market share data. Competitors include Bayer (Nexavar) and Eisai (Lenvima).
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and personalized medicine. The market is highly competitive, with many companies vying for market share.
Positioning
Tiziana Life Sciences Ltd is positioned as a clinical-stage biotechnology company with a focus on innovative therapeutics. Its competitive advantages include its novel pipeline of drug candidates and its experienced management team.
Total Addressable Market (TAM)
The TAM for oncology, inflammation, and infectious diseases is estimated to be in the hundreds of billions of dollars. Tiziana Life Sciences Ltd is positioned to capture a portion of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel pipeline of drug candidates
- Experienced management team
- Focus on unmet medical needs
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Lack of commercial infrastructure
- Small Market Cap
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
- Favorable regulatory environment
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- GILD
- BMY
Competitive Landscape
Tiziana Life Sciences Ltd faces significant competition from larger pharmaceutical companies with established products and greater resources. However, its innovative pipeline and targeted therapies offer potential competitive advantages.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its pipeline candidates through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential commercialization of its drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the advancement of Foralumab into Phase 2 trials for Crohn's disease and NASH, and the development of inhaled Foralumab for COVID-19.
Summary
Tiziana Life Sciences is a high-risk, high-reward clinical-stage biotech company with a novel pipeline. Its success hinges on positive clinical trial outcomes, and its limited financial resources pose a challenge. While the company has an innovative portfolio, it needs strategic partnerships and acquisitions to thrive given its size and competition from big pharma.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tiziana Life Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2000-03-24 | CEO & Executive Director Dr. Ivor R. Elrifi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | |
Full time employees 9 | |||
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.